Diatide partner Angstrom wins cancer patent

Article

Therapeutic radiopharmaceutical developer Angstrom Pharmaceuticals has won a patent for the treatment of metastatic cancer, according to research partner Diatide. The patent strengthens both companies’ efforts to develop anticancer therapeutic

Therapeutic radiopharmaceutical developer Angstrom Pharmaceuticals has won a patent for the treatment of metastatic cancer, according to research partner Diatide. The patent strengthens both companies’ efforts to develop anticancer therapeutic products.

In March, Diatide and Angstrom created a license agreement that gives Diatide exclusive rights to tumor imaging and anticancer therapeutics based on Angstrom’s uPAR (urokinase plasminogen activator receptor) targeting technology. The agreement stipulates that Diatide will pay Angstrom research and milestone payments, as well as royalties on product sales (SCAN 4/28/99). The firms are working together on research that combines Diatide’s peptide analog development expertise with Angstrom’s knowledge of uPAR-binding peptides.

UPAR is found on the surface of almost all solid tumors, including breast, prostate, colon, and lung. The two firms believe that targeting these receptors with radiotherapeutic agents could obstruct tumor growth. Angstrom’s latest patent covers a broad class of cyclic peptides that bind to uPAR.

In other Diatide news, the Londonderry, NH, company’s NeoTect lung tumor agent has begun shipping. NeoTect received Food and Drug Administration clearance last month (SCAN 8/18/99). Diatide has a marketing partnership with Nycomed Amersham, although the Buckinghamshire, U.K., firm sold its share in the U.S. company in June (SCAN 6/23/99).

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.